Quotient Investors LLC Maintains Position in Gilead Sciences, Inc. (GILD)

Quotient Investors LLC maintained its stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, Holdings Channel reports. The institutional investor owned 14,832 shares of the biopharmaceutical company’s stock at the end of the second quarter. Quotient Investors LLC’s holdings in Gilead Sciences were worth $1,007,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Meyer Handelman Co. boosted its stake in Gilead Sciences by 1.7% in the second quarter. Meyer Handelman Co. now owns 387,500 shares of the biopharmaceutical company’s stock worth $27,426,000 after buying an additional 6,600 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its stake in Gilead Sciences by 1.4% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 101,719 shares of the biopharmaceutical company’s stock worth $7,199,000 after buying an additional 1,380 shares during the period. US Bancorp DE boosted its stake in Gilead Sciences by 16.5% in the second quarter. US Bancorp DE now owns 1,022,039 shares of the biopharmaceutical company’s stock worth $72,340,000 after buying an additional 144,403 shares during the period. Harvey Capital Management Inc. boosted its stake in Gilead Sciences by 0.3% in the second quarter. Harvey Capital Management Inc. now owns 116,260 shares of the biopharmaceutical company’s stock worth $8,228,000 after buying an additional 300 shares during the period. Finally, Bennicas & Associates Inc. boosted its stake in Gilead Sciences by 0.4% in the second quarter. Bennicas & Associates Inc. now owns 22,600 shares of the biopharmaceutical company’s stock worth $1,600,000 after buying an additional 100 shares during the period. Institutional investors own 74.06% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) traded down 0.88% during mid-day trading on Friday, reaching $72.06. 3,666,513 shares of the company’s stock were exchanged. The stock has a market cap of $94.11 billion, a price-to-earnings ratio of 7.83 and a beta of 1.21. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $82.10. The stock has a 50 day moving average price of $72.31 and a 200 day moving average price of $68.76.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the previous year, the business earned $3.08 EPS. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year. Equities research analysts predict that Gilead Sciences, Inc. will post $8.76 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.86%. Gilead Sciences’s dividend payout ratio is presently 22.58%.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2802272/quotient-investors-llc-maintains-position-in-gilead-sciences-inc-gild.html.

A number of analysts recently commented on the stock. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a research note on Friday, July 28th. Cowen and Company reiterated an “outperform” rating and issued a $90.00 target price on shares of Gilead Sciences in a research note on Thursday, July 27th. Deutsche Bank AG reiterated a “buy” rating and issued a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $82.00 target price (up from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Twelve research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $80.31.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold a total of 206,666 shares of company stock worth $15,223,184 over the last 90 days. 1.30% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.